Unresectable primary lung cancer remains one of the most formidable problems in oncology. Despite the use of chemotherapy and radiation therapy in combined modality protocols, local control rates are less that 20 percent. Locally gene advanced NSCLC represents an excellent therapeutic target and model system for a clinical protocol involving gene transfer. A large volume of preclinical and the Phase I clinical trial data for adenoviral vector expressing wildtype p53 (Ad-p53) support the initiation of a clinical trial to test the hypothesis that: 1) over-expression of wildtype p53 in non-small cell lung cancer (NSCLC) cells will enhance sensitivity to external beam ionizing radiation, and 2) that the combination therapy will improve local control and ultimately survival in NSCLC. The design of this trial will take into consideration the possibility that adverse events related to the combination of Ad-p53 and radiation not seen with Ad-p53 alone could occur and will assess this first with a small run-in dose escalation study. This will be followed by a Phase II clinical trial to address the following specific aims:
Aim number 1: To determine if the intralesional administration of Ad-p53 in conjunction with primary radiation therapy increases local tumor control in patients with non-small cell lung cancer, and in follow-up randomized clinical trial, to determine if induction chemotherapy, radiation therapy, and intralesional Ad-p53 increases local tumor control and survival compared to induction chemotherapy and radiation therapy only.
Aim number 2: To determine the qualitative and quantitative toxicity and reversibility of toxicity following intralesional administration of Ad-p53 in conjunction with radiation therapy in patients with non-small cell lung cancer.
Aim number 3: To conduct laboratory experiments to validate that the vectors proposed, Adv-p53 and others, function to sensitize cells derived from various human tumors to radiation both in vitro and in vivo.
Aim number 4: To conduct mechanistic studies to determine the biochemical pathways activated in cells following gene therapy responsible for restoring apoptosis propensity and radiosensitization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA078778-01A1
Application #
6232825
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-07-23
Project End
2004-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Pataer, Apar; Kalhor, Neda; Correa, Arlene M et al. (2012) Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7:825-32
Kadowaki, Yoshihiko; Chari, Nikhil S; Teo, Albert E K et al. (2011) PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells. Apoptosis 16:627-35
Pataer, Abujiang; Swisher, Stephen G; Roth, Jack A et al. (2009) Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8:245-52
Pataer, Abujiang; Chada, Sunil; Roth, Jack A et al. (2008) Development of Ad-mda7/IL-24-resistant lung cancer cell lines. Cancer Biol Ther 7:103-8
Pataer, Abujiang; Hu, Wenxian; Xiaolin, Lu et al. (2008) Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 7:2528-35
Pataer, A; Bocangel, D; Chada, S et al. (2007) Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue. Cancer Gene Ther 14:12-8
Peng, Henry H; Wu, Shuhong; Davis, John J et al. (2006) A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. Anal Biochem 354:140-7
Pataer, A; Fanale, M A; Roth, J A et al. (2006) Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 13:806-14
Li, Zhongkui; Niu, Jiangong; Uwagawa, Tadashi et al. (2005) Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response. J Biol Chem 280:16843-50
Sclabas, Guido M; Fujioka, Shuichi; Schmidt, Christian et al. (2005) Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11:440-9

Showing the most recent 10 out of 88 publications